
### [NCIT:C3212](http://purl.obolibrary.org/obo/NCIT_C3212)
**Label:** Lymphoplasmacytic Lymphoma

**Subclasses:** [NCIT:C8604](http://purl.obolibrary.org/obo/NCIT_C8604) (Recurrent Lymphoplasmacytic Lymphoma), [NCIT:C8656](http://purl.obolibrary.org/obo/NCIT_C8656) (Stage IV Lymphoplasmacytic Lymphoma), [NCIT:C7305](http://purl.obolibrary.org/obo/NCIT_C7305) (Splenic Lymphoplasmacytic Lymphoma), [NCIT:C8654](http://purl.obolibrary.org/obo/NCIT_C8654) (Stage II Lymphoplasmacytic Lymphoma), [NCIT:C115212](http://purl.obolibrary.org/obo/NCIT_C115212) (Familial Waldenstrom Macroglobulinemia), [NCIT:C8655](http://purl.obolibrary.org/obo/NCIT_C8655) (Stage III Lymphoplasmacytic Lymphoma), [NCIT:C127840](http://purl.obolibrary.org/obo/NCIT_C127840) (Recurrent Waldenstrom Macroglobulinemia), [NCIT:C8652](http://purl.obolibrary.org/obo/NCIT_C8652) (Refractory Lymphoplasmacytic Lymphoma), [NCIT:C8653](http://purl.obolibrary.org/obo/NCIT_C8653) (Stage I Lymphoplasmacytic Lymphoma), [NCIT:C80307](http://purl.obolibrary.org/obo/NCIT_C80307) (Waldenstrom Macroglobulinemia), 

**Class expressions from DL-Learner:**

- Thing 54.38%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) 37.02%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39905](http://purl.obolibrary.org/obo/NCIT_C39905) (Prostate Stromal Proliferation of Uncertain Malignant Potential))) 37.02%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39903](http://purl.obolibrary.org/obo/NCIT_C39903) (Prostate Adenocarcinoma with Focal Neuroendocrine Differentiation))) 37.02%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39902](http://purl.obolibrary.org/obo/NCIT_C39902) (Prostate Basal Cell Carcinoma))) 37.02%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39901](http://purl.obolibrary.org/obo/NCIT_C39901) (Prostatic Duct Urothelial Carcinoma))) 37.02%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39899](http://purl.obolibrary.org/obo/NCIT_C39899) (Secondary Prostate Urothelial Carcinoma))) 37.02%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39897](http://purl.obolibrary.org/obo/NCIT_C39897) (Prostate Ductal Adenocarcinoma, Solid Pattern))) 37.02%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39896](http://purl.obolibrary.org/obo/NCIT_C39896) (Prostate Ductal Adenocarcinoma, Papillary Pattern))) 37.02%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39895](http://purl.obolibrary.org/obo/NCIT_C39895) (Prostate Ductal Adenocarcinoma, Cribriform Pattern))) 37.02%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C3989](http://purl.obolibrary.org/obo/NCIT_C3989) (Parathyroid Hyperplasia))) 37.02%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39885](http://purl.obolibrary.org/obo/NCIT_C39885) (Acinar Prostate Adenocarcinoma, Lymphoepithelioma-Like Variant))) 37.02%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39880](http://purl.obolibrary.org/obo/NCIT_C39880) (Acinar Prostate Adenocarcinoma, Atrophic Variant))) 37.02%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39875](http://purl.obolibrary.org/obo/NCIT_C39875) (Loss of Chromosome 9q))) 37.02%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39874](http://purl.obolibrary.org/obo/NCIT_C39874) (Urethral Verrucous Carcinoma))) 37.02%


